Published in final edited form as:

Biochem Biophys Res Commun. 2018 September 10; 503(3): 1498–1502. doi:10.1016/j.bbrc.2018.07.069.

Citrullinated Histone 3 Causes Endothelial Barrier Dysfunction

Jamie E. Meegan^a, Xiaoyuan Yang^a, Richard S. Beard Jr.^a, Melanie Jannaway^a, Victor Chatterjee^a, Thomas E. Taylor-Clark^a, and Sarah Y. Yuan^{a,b}

^aDepartment of Molecular Pharmacology & Physiology, University of South Florida Morsani College of Medicine, Tampa, FL, USA

^bDepartment of Surgery, University of South Florida Morsani College of Medicine, Tampa, FL, USA

Abstract

Circulating components of neutrophil extracellular traps (NETs), especially histones, are associated with tissue injury during inflammatory conditions like sepsis. Commonly used as a NET biomarker, citrullinated histone 3 (H3Cit) may also functionally contribute to the NET-associated inflammatory response. To this end, we sought to examine the role of H3Cit in mediating microvascular endothelial barrier dysfunction. Here we show that H3Cit can directly contribute to inflammatory injury by disrupting the microvascular endothelial barrier. We found that endothelial responses to H3Cit are characterized by cell-cell adherens junction opening and cytoskeleton reorganization with increased F-actin stress fibers. Several signaling pathways often implicated in the transduction of hyperpermeability, such as Rho and MLCK, did not appear to play a major role; however, the adenylyl cyclase activator forskolin blocked the endothelial barrier effect of H3Cit. Taken together, the data suggest that H3Cit-induced endothelial barrier dysfunction may hold promise to treat inflammatory injury.

Keywords

H3Cit; microcirculation; permeability; adherens junction; cytoskeleton

Introduction

Circulating extracellular histones are associated with tissue injury during the systemic inflammatory response to infection [1] or trauma [2]. While histones are generally located within the cell nucleus, they can be released into the circulation or tissues upon cell injury or programmed death, especially during the release of neutrophil extracellular traps (NETs) [3]. NETosis is a unique cell death mechanism initiated by the peptidylarginine deiminase 4

Correspondence: Sarah Yuan, MD, PhD, Chair, Department of Molecular Pharmacology & Physiology, Professor of Surgery, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, MDC 8, Tampa, FL 33612, 813-974-5104, 813-974-3079 (Fax), syuan@health.usf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

(PAD4)-mediated citrullination of histone 3, which causes decondensation of chromatin and subsequent release of a DNA-web containing histones, proteases, and other granular or cytoplasmic contents [3, 4]. Components of NETs, including histones, have been shown to increase in the circulation during many inflammatory conditions including sepsis [5], acute lung injury [6, 7], autoimmune diseases [8], and cancer [9], damaging vasculature by promoting coagulopathy [10, 11] and vascular barrier dysfunction [12, 13].

Representing a common endpoint in a number of inflammatory injuries, endothelial barrier dysfunction causes fluid leakage and leukocyte infiltration that leads to tissue damage and multiple organ failure [14, 15]. Elucidating the molecular mechanisms of endothelial barrier regulation is needed to further develop targeted therapies in inflammatory disease. While there is no specific marker of NETs, citrullinated histone 3 (H3Cit) has been recognized as a key component to determine the presence of NETs and has been proposed as an inflammatory biomarker [16], as it has been shown to increase in mice and humans during various inflammatory states [17, 18]. Interestingly, H3Cit could have causative effects on tissue injury, as it has been shown that injection of either pharmacological PAD inhibitors [18, 19] or H3Cit antibody [20] can improve outcomes of systemic inflammation. To this end, we sought to determine the direct effects H3Cit might have on the endothelial barrier.

Materials and Methods

Animals

Mice used in these studies were male C57BL/6J purchased from Jackson Laboratory. Genotyping was performed by Transnetyx using real-time PCR. Mice were maintained under a 12/12-hour light/dark cycle with food and water *ad libitum*. All animal studies were approved by the University of South Florida Institutional Animal Care and Use Committee and was performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

Intravital microscopic analysis of protein transvascular flux

To examine plasma protein flux across mesenteric microvessels [21], mice (10–20g) were anesthetized with an intramuscular injection of urethane (1.75 g/kg) and shaved at the abdomen. The jugular vein was cannulated for IV infusion of solutions. A midline laparotomy was performed, and the mesentery was exteriorized over an optical stage for microscopic observation. The microcirculation of the mesentery was imaged using a Nikon Eclipse E600FN microscope with Evolve 512 digital camera (Photometrics, AZ, USA). Mice were given an IV bolus of fluorescein isothiocyanate conjugated bovine albumin (FITC-albumin) at 100 mg/kg followed by continuous infusion of 0.15 mg/kg/min to maintain a constant plasma concentration. Postcapillary venules were selected for analysis of FITC-albumin flux and stimulated with 10 µg/mL recombinant H3Cit or vehicle control. FITC-albumin leaking into extra-vascular space was accumulated over time. Fluorescent images were acquired every five minutes for one hour. Protein flux was quantified using the formula $IOI_{Rel} = (I_i - I_o) / I_i$, where I_i = intensity inside the vessel and I_o = intensity outside the vessel.

HUVEC cell culture

Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza and grown in Endothelial Cell Basal Medium supplemented with EGM-2 MV Bulletkits (Lonza, MD, USA), or from PromoCell and grown in Endothelial Cell Growth Medium 2 supplemented with SupplementMix C-39216 (PromoCell GmbH, Heidelberg, Germany). Cells were seeded onto 0.1% gelatin-coated plates and incubated in 5% CO₂ humidified incubator at 37°C for 2–3 days past confluence for use in experimental assays.

Transendothelial electrical resistance

HUVECs were seeded onto 8W10E+ PET electrode arrays to be used with an Electric Cell-Substrate Impedance Sensing (ECIS) system (Applied Biophysics, Troy, NY).

Transendothelial electrical resistance (TER) was continuously recorded over time as an indicator of cell-cell adhesive barrier function [22]. Cells were stimulated with human recombinant H3Cit (Item No. 17926; Cayman Chemical, Ann Arbor, MI) or vehicle control (0.1% BSA in PBS) with or without inhibitors. Representative tracings are presented normalized to baseline. Change in resistance was quantified by subtracting the lowest resistance value from the baseline resistance value of each ECIS well and averaging maximum change from baseline at each concentration. Inhibitors used in this study include Rho kinase inhibitor Y27632 (Cayman), Rho inhibitor Rhosin (Calbiochem), and MLCK inhibitor peptide 18 (Cayman). Barrier enhancing agent forskolin (MP Biomedicals) was used as a pharmacological therapeutic.

Cell Viability Assay

LIVE/DEAD™ Viability/Cytotoxicity Kit, for mammalian cells (Cat. No L3224; Invitrogen) was used per manufacturer's instructions. Absorbance was read at 530 nm (calcein AM) to determine live cells and at 645 nm (ethidium homodimer-1) to determine dead cells.

Immunofluorescence confocal microscopy

HUVECs were seeded onto coverslips and treated with human recombinant H3Cit or vehicle control for one minute for immunofluorescence staining as we've previously described. For adherens junction staining, cells were fixed with 4% paraformaldehyde for 10 minutes at room temperature, washed twice with PBS, blocked with 10% donkey serum in PBS for one hour, and labeled with VE-cadherin (D87F2) XP® Rabbit mAb #2500 (CST; 1:500) overnight at 4°C in a humidified chamber. The next day, cells were washed with PBS, incubated with donkey anti-rabbit IgG Alexa Fluor 488 (Invitrogen; Cat #R37118) for one hour at room temperature, washed again with PBS, and mounted to slides with ProLong Diamond Antifade Mountant with DAPI (Life Technologies). Fluorescent confocal images were captured with an Olympus FV1200 Laser Scanning Confocal Microscope. VE-cadherin intensity was analyzed with FIJI (version 2.0.0-rc-65/1.51w) software by taking the sum of Z-stack (6 slices), subtracting the background (radius=10), applying Gaussian blur (1.00), converting to mask, and analyzing the particles (size 50-Infinity, circularity 0–0.25) per field of view (~212 µm²). Actin staining was performed in the same manner, except cells were permeabilized with 0.1% PBS-T for 5 minutes before blocking and were stained with Alexa Fluor 568 Phalloidin (F-actin) and Alexa Fluor 488 DNase I (G-actin) for 20 minutes

at room temperature. Intensity of each type of actin was analyzed using FIJI (version 2.0.0-rc-65/1.51w) software by taking the sum of Z-stack (10 slices) and measuring total intensity per field of view ($\sim 318 \mu\text{m}^2$), represented as F:G-actin ratio.

Statistical analysis

Statistics were performed using GraphPad Prism (version 6.0f/7.0d). Pairwise-comparisons were made using unpaired two-tailed t-test and group-wise comparisons were made using ordinary one-way ANOVA with Tukey's post hoc multiple comparisons test. Statistical significance was defined as $p < 0.05$.

Results and Discussion

H3Cit causes microvascular leakage and endothelial barrier dysfunction without cell death

To determine the direct effects of H3Cit in the microvascular endothelial barrier, we used intravital microscopy to examine the protein transvascular flux and found that H3Cit ($10 \mu\text{g/mL}$) caused extravasation of fluorescent-labeled albumin across microvessels (Fig. 1). Furthermore, we used the ECIS system to measure TER, an indicator of cell-cell adhesive barrier strength and found that stimulation of HUVECs with H3Cit decreased TER in a concentration-dependent manner, indicating endothelial barrier dysfunction (Fig. 2A and B); this response was not due to cell death (Fig. 2C). Taken together, we concluded that H3Cit is capable of disrupting the microvascular endothelial barrier without causing cell toxicity.

H3Cit-mediated endothelial barrier dysfunction is not dependent on Rho or MLCK signaling pathways

Limited information is available regarding the receptor and signaling mechanisms underlying histone-induced endothelial injury. Similar to other components of NETs, such as extracellular DNA, histones can be considered to act as a pattern recognition molecule. So far, cellular pathways seemingly activated by extracellular histones include toll-like receptor [23, 24] and inflammasome [25, 26] signaling, as well as membrane integration and calcium influx [2, 27]. However, modifications of histones can affect their size, charge, and structure [28], which could change the way they interact with the endothelium. For example, we were unable to prevent H3Cit-induced endothelial barrier dysfunction with TLR4 antagonism (data not shown). Thus, it is important to distinguish the specific effects of different histones like H3Cit that are modified during pathological conditions so that more specific targeted therapies can be developed.

In attempt to determine the signaling events responsible for H3Cit-mediated endothelial barrier dysfunction, we investigated two well-known pathways involved in barrier regulation, namely the Rho and myosin light chain kinase (MLCK) pathways. Endothelial paracellular permeability is dynamically regulated by intercellular junctions that are anchored to the cytoskeleton where the activation status of myosin light chain (MLC) determines the contractile status of cells. MLC phosphorylation, which can be increased by both the Rho (MLC phosphatase inhibition) and MLCK (MLC kinase activation) signaling pathways, triggers cell contraction and subsequent junction opening [22]. Surprisingly, inhibition of Rho pathway with rho-associated protein kinase (ROCK) inhibitor Y27632

(Fig. 2D) or Rho GEF binding domain inhibitor Rhosin (Fig. 2E) was not sufficient to prevent the TER drop induced by H3Cit. Similarly, inhibition of MLCK pathway with MLCK inhibitor peptide 18 was unable to reduce H3Cit-mediated endothelial barrier dysfunction (Fig. 2F). Therefore, we suggest that H3Cit-induced barrier opening is not dependent on MLCK or Rho activity; rather, it may affect through actin polymerization.

H3Cit causes EC barrier dysfunction by opening adherens junctions and reorganizing the actin cytoskeleton

To further investigate potential molecular mechanisms of H3Cit-induced barrier dysfunction, we sought to determine its effects on endothelial cell-cell adherens junctions and the actin cytoskeleton. Polymerization and redistribution of the actin cytoskeleton to form stress fibers in endothelial cells promotes the opening of cell-cell junctions [29]. Stimulation of HUVECs with H3Cit caused rapid thinning of adherens junction protein VE-cadherin at cell-cell borders coupled with intercellular gap formation (Fig. 3A and B). Furthermore, H3Cit invoked centralized F-actin bundles and an increase in the ratio of filamentous (F)-actin to globular (G)-actin, indicating actin stress fiber formation (Fig. 3C and D). In consistence with our finding, histones have recently been shown to polymerize G-actin and bundle with F-actin [30], supporting the possibility of histone-actin interactions and subsequent endothelial barrier opening. We conclude that H3Cit contributes to endothelial barrier dysfunction by opening adherens junctions and reorganizing the actin cytoskeleton.

Barrier-enhancing adenylyl cyclase activator forskolin prevents H3Cit-mediated barrier disruption

Although the precise endothelial cell signaling mechanisms activated by H3Cit responsible for barrier dysfunction warrants further investigation, we sought to determine whether a known barrier enhancer was capable of preventing the response therapeutically. The pharmacological agent forskolin, typically recognized as a barrier enhancer due to its activation of adenylyl cyclase, contributes to actin cytoskeleton stabilization [29]. Indeed, enhancing the endothelial barrier with forskolin (10 μ M, 30 min pre-treatment) substantially attenuated the TER response to H3Cit (Fig. 4A and B). Therefore, enhancing the endothelial barrier therapeutically by stabilizing the actin cytoskeleton may be an option to protect against H3Cit-mediated tissue injury.

In summary, this study demonstrates novel evidence for H3Cit-induced endothelial barrier dysfunction leading to microvascular leakage characterized by opening of adherens junctions and reorganization of the actin cytoskeleton; the response can be prevented by enhancing the barrier with the adenylyl cyclase activator forskolin. Targeting H3Cit therapeutically may hold potential to limit the exacerbation of the inflammatory response during a number of conditions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Danielle Coleman and Jonathan Overstreet for their technical assistance and Byeong J. Cha from the USF Health Lisa Muma Weitz Laboratory for Advanced Microscopy and Cell Imaging for confocal imaging assistance.

Funding: This work was supported by the National Institutes of Health [grant numbers HL126646, HL070752, and GM097270].

References

- [1]. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT, Extracellular histones are major mediators of death in sepsis, *Nature medicine*, 15 (2009) 1318–1321.
- [2]. Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F, Wang SS, Brohi K, Kipar A, Yu W, Wang G, Toh CH, Circulating histones are mediators of trauma-associated lung injury, *American journal of respiratory and critical care medicine*, 187 (2013) 160–169. [PubMed: 23220920]
- [3]. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A, Neutrophil extracellular traps kill bacteria, *Science (New York, N.Y.)*, 303 (2004) 1532–1535.
- [4]. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, Hayama R, Leonelli L, Han H, Grigoryev SA, Allis CD, Coonrod SA, Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation, *The Journal of cell biology*, 184 (2009) 205–213. [PubMed: 19153223]
- [5]. Czaikoski PG, Mota JM, Nascimento DC, Sonogo F, Castanheira FV, Melo PH, Scortegagna GT, Silva RL, Barroso-Sousa R, Souto FO, Pazin-Filho A, Figueiredo F, Alves-Filho JC, Cunha FQ, Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis, *PloS one*, 11 (2016) e0148142. [PubMed: 26849138]
- [6]. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, Toy P, Werb Z, Looney MR, Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury, *The Journal of clinical investigation*, 122 (2012) 2661–2671. [PubMed: 22684106]
- [7]. Bosmann M, Grailer JJ, Ruemmler R, Russkamp NF, Zetoune FS, Sarma JV, Standiford TJ, Ward PA, Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury, *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 27 (2013) 5010–5021. [PubMed: 23982144]
- [8]. Villanueva E, Yalavarthi S, Berthier CC, Hodgins JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ, Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus, *Journal of immunology (Baltimore, Md. : 1950)*, 187 (2011) 538–552.
- [9]. Berger-Achituv S, Brinkmann V, Abed UA, Kuhn LI, Ben-Ezra J, Elhasid R, Zychlinsky A, A proposed role for neutrophil extracellular traps in cancer immunoediting, *Frontiers in immunology*, 4 (2013) 48. [PubMed: 23508552]
- [10]. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., Wroblewski SK, Wakefield TW, Hartwig JH, Wagner DD, Extracellular DNA traps promote thrombosis, *Proceedings of the National Academy of Sciences of the United States of America*, 107 (2010) 15880–15885. [PubMed: 20798043]
- [11]. Borissoff JI, Joosen IA, Versteylen MO, Brill A, Fuchs TA, Savchenko AS, Gallant M, Martinod K, Ten Cate H, Hofstra L, Crijns HJ, Wagner DD, Kietzelaer B, Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state, *Arteriosclerosis, thrombosis, and vascular biology*, 33 (2013) 2032–2040.
- [12]. Pieterse E, Rother N, Garsen M, Hofstra JM, Satchell SC, Hoffmann M, Loeven MA, Knaapen HK, van der Heijden OWH, Berden JHM, Hilbrands LB, van der Vlag J, Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition, *Arteriosclerosis, thrombosis, and vascular biology*, 37 (2017) 1371–1379.

- [13]. Meegan JE, Yang X, Coleman DC, Jannaway M, Yuan SY, Neutrophil-mediated vascular barrier injury: Role of neutrophil extracellular traps, *Microcirculation* (New York, N.Y. : 1994), 24 (2017).
- [14]. Opal SM, van der Poll T, Endothelial barrier dysfunction in septic shock, *Journal of internal medicine*, 277 (2015) 277–293. [PubMed: 25418337]
- [15]. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY, Molecular mechanisms of endothelial hyperpermeability: implications in inflammation, *Expert reviews in molecular medicine*, 11 (2009) e19. [PubMed: 19563700]
- [16]. Pan B, Alam HB, Chong W, Mobley J, Liu B, Deng Q, Liang Y, Wang Y, Chen E, Wang T, Tewari M, Li Y, CitH3: a reliable blood biomarker for diagnosis and treatment of endotoxic shock, *Scientific reports*, 7 (2017) 8972. [PubMed: 28827548]
- [17]. Hirose T, Hamaguchi S, Matsumoto N, Irisawa T, Seki M, Tasaki O, Hosotsubo H, Yamamoto N, Yamamoto K, Akeda Y, Oishi K, Tomono K, Shimazu T, Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients, *PloS one*, 9 (2014) e111755. [PubMed: 25392950]
- [18]. Biron BM, Chung CS, O'Brien XM, Chen Y, Reichner JS, Ayala A, Cl-Amidine Prevents Histone 3 Citrullination and Neutrophil Extracellular Trap Formation, and Improves Survival in a Murine Sepsis Model, *Journal of innate immunity*, 9 (2017) 22–32. [PubMed: 27622642]
- [19]. Zhao T, Pan B, Alam HB, Liu B, Bronson RT, Deng Q, Wu E, Li Y, Protective effect of Cl-amidine against CLP-induced lethal septic shock in mice, *Scientific reports*, 6 (2016) 36696. [PubMed: 27819302]
- [20]. Li Y, Liu Z, Liu B, Zhao T, Chong W, Wang Y, Alam HB, Citrullinated histone H3: a novel target for the treatment of sepsis, *Surgery*, 156 (2014) 229–234. [PubMed: 24957671]
- [21]. Beard RS, Yang X, Meegan JE, Overstreet JW, Yang CGY, Elliott JA, Reynolds JJ, Cha BJ, Pivetti CD, Mitchell DA, Wu MH, Deschenes RJ, Yuan SY, Palmitoyl acyltransferase DHHC21 mediates endothelial dysfunction in systemic inflammatory response syndrome, *Nature Communications*, 7 (2016) 12823.
- [22]. Yuan SY, Rigor RR, *Integrated Systems Physiology: From Molecule to Function to Disease, Regulation of Endothelial Barrier Function*, Morgan & Claypool Life Sciences Copyright (c) 2011 by Morgan & Claypool Life Sciences., San Rafael (CA), 2010.
- [23]. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT, Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury, *Journal of immunology* (Baltimore, Md. : 1950), 187 (2011) 2626–2631.
- [24]. Huang H, Evankovich J, Yan W, Nace G, Zhang L, Ross M, Liao X, Billiar T, Xu J, Esmon CT, Tsung A, Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice, *Hepatology* (Baltimore, Md.), 54 (2011) 999–1008.
- [25]. Huang H, Chen HW, Evankovich J, Yan W, Rosborough BR, Nace GW, Ding Q, Loughran P, Beer-Stolz D, Billiar TR, Esmon CT, Tsung A, Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury, *Journal of immunology* (Baltimore, Md. : 1950), 191 (2013) 2665–2679.
- [26]. Allam R, Darisipudi MN, Tschopp J, Anders HJ, Histones trigger sterile inflammation by activating the NLRP3 inflammasome, *European journal of immunology*, 43 (2013) 3336–3342. [PubMed: 23964013]
- [27]. Kalbitz M, Grailer JJ, Fattahi F, Jajou L, Herron TJ, Campbell KF, Zetoune FS, Bosmann M, Sarma JV, Huber-Lang M, Gebhard F, Loaiza R, Valdivia HH, Jalife J, Russell MW, Ward PA, Role of extracellular histones in the cardiomyopathy of sepsis, *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 29 (2015) 2185–2193. [PubMed: 25681459]
- [28]. Xu YM, Du JY, Lau AT, Posttranslational modifications of human histone H3: an update, *Proteomics*, 14 (2014) 2047–2060. [PubMed: 25044606]
- [29]. Yuan SY, Protein kinase signaling in the modulation of microvascular permeability, *Vascular Pharmacology*, 39 (2002) 213–223. [PubMed: 12747961]
- [30]. Blotnick E, Sol A, Muhrad A, Histones bundle F-actin filaments and affect actin structure, *PloS one*, 12 (2017) e0183760. [PubMed: 28846729]

Highlights

- We report a new function of citrullinated histones
- H3Cit mediates microvascular leakage and endothelial barrier dysfunction
- H3Cit causes cell-cell junction disorganization and actin stress fiber formation
- H3Cit-mediated barrier dysfunction is not due to cell death or Rho/MLCK signaling
- Adenylyl cyclase activator forskolin blocks H3Cit-induced barrier dysfunction

Figure 1. H3Cit causes microvascular leakage of mouse mesenteric microvessels.

(A) Captured images during intravital microscopy of mice injected with FITC-albumin to observe microvascular leakage of mesenteric microvessels stimulated with H3Cit (10 μ g/mL). (B) Quantification of transvascular flux ($p < 0.0001$) using the equation $IOI_{Rel} = (I_i - I_o)/I_i$, where I_i =intensity inside the vessel and I_o =intensity outside the vessel. Data represented as mean $\pm$ S.E.M. (n=4); * = $p < 0.05$ vs Vehicle.

Figure 2. H3Cit causes endothelial barrier dysfunction that is not dependent on cell death, Rho, or MLCK.

(A) Representative tracing of TER and (B) average maximum TER drop ($p < 0.0001$) of HUVEC monolayers in response to increasing concentrations of H3Cit. Data represented as mean - S.E.M. ($n = 6-12$); * = $p < 0.05$ vs Vehicle. (C) LIVE/DEAD cell viability assay (absorbance at 530 nm of calcein AM to determine live cells and at 645 nm of ethidium homodimer-1 to determine dead cells; $p < 0.0001$) [No tx = no treatment, (+) = positive control (70% methanol), Veh = vehicle control (0.1% BSA in PBS)]. (D-F) Average maximum TER drop of HUVEC monolayers in response to H3Cit (10 $\mu\text{g/mL}$) and Rho pathway inhibition by (D) Y27632 (10 μM , 30 min pre-treatment; $p < 0.0001$) or (E) Rhosin (30 μM , 30 min pre-treatment; $p < 0.0001$), or (F) MLCK pathway inhibition by MLCK inhibitor peptide 18 (10 μM , 30 min pre-treatment; $p < 0.0001$). Data represented as mean - S.E.M. ($n = 8-12$); * = $p < 0.05$ vs Vehicle; ns = not significant.

Figure 3. H3Cit causes endothelial barrier dysfunction by opening cell-cell adherens junctions and reorganizing the actin cytoskeleton.

(A) Immunofluorescence images and (B) intensity quantification of adherens junction protein VE-cadherin (green) at cell borders in HUVECs stimulated with H3Cit (10 µg/mL) for 1 minute ($p=0.0026$). Arrows indicate thinned segments. (C) Immunofluorescence images of F-actin (white) and G-actin (green) in HUVECs stimulated with H3Cit (10 µg/mL) for 1 minute and (D) quantification of the ratio of F-actin to G-actin ($p=0.0074$), indicating actin polymerization. Data represented as mean + S.E.M. ($n=3$); * = $p<0.05$ vs Vehicle.

Figure 4. H3Cit-mediated endothelial barrier dysfunction can be prevented by adenylyl cyclase activator forskolin.

(A) Representative tracing and (B) average maximum TER drop of HUVEC monolayers in response to H3Cit (10 μ g/mL) and barrier enhancement with forskolin (10 μ M, 30 min pre-treatment; $p < 0.0001$). Data represented as mean - S.E.M. ($n = 6-8$); * = $p < 0.05$ vs Vehicle, # = $p < 0.05$ vs H3Cit.